hotspot -WSS

hotspot

author：explore 2025-09-06 03:50:54 - browse：63195

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Eisai exec who led development of Alzheimer’s drug to retire

WSS

White House announces new plan to address the growing threat of xylazine in overdose crisis

What would happen to your eyes if you looked at the solar eclipse?

Cloning humans is technically possible. It's curious no one has tried

With FDA staff opposed to Sarepta therapy, top official intervened

Why we need to separate burnout from moral injury in health care

Judge agrees to delay next hearing in Trump classified documents case

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Alkermes shareholders re

Presidential fundraising highlights so far: Trump brings in more than DeSantis

United colonoscopy coverage change 'may cost lives,' doctors say

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

United colonoscopy coverage change 'may cost lives,' doctors say

#NeedHerScience: shining a light on gender disparities in medicine

New air purifier tech could be key to improving indoor air quality

In areas with more Black doctors, Black people live longer

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biden’s NIH nominee is languishing in Congress

hotspot

Wisconsin governor employs partial veto to fund schools for 4 centuries

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Biden’s NIH nominee is languishing in Congress

Recent heat wave in the Mediterranean caused by climate change: Study

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

knowledge

entertainment

knowledge

hotspot